Aug 11, 2025, 12:23
Ashley Love Sumrall: First FDA-approved Treatment for H3K27M Diffuse Midline Glioma
Ashley Love Sumrall, Section Chief of Neuro-Oncology at the Atrium Health Levine Cancer, shared, shared a post on X:
“Just over 5y ago, I started treating patients with H3K27M midline glioma.
Our team had the opportunity to open a trial with ONC201 or dordaviprone. We have learned so much over the years, and I was honored to present data in june ASCO25 today.
Dordaviprone is FDA-approved as the FIRST treatment for kids and adults with H3K27m diffuse midline glioma!
SO grateful for the teams involved and our courageous patients with families.”
More posts featuring Ashley Love Sumrall on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Sep 2, 2025, 20:50
Sep 2, 2025, 18:53
Sep 2, 2025, 16:54
Sep 2, 2025, 16:41